, Singapore
357 views
Photo from A*STAR

BioNTech joins Biologics Pharma Innovation Programme Singapore consortium

The consortium aims to grow Singapore’s capabilities in biologics manufacturing.

The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium welcomed global immunotherapy company BioNTech to its roster of members.

The consortium, led by A*STAR, aims to increase productivity and sustainability in biologics manufacturing, transforming the existing base of biologics production in Singapore. 

The consortium focuses on biologics products, including recombinant therapeutic proteins and vaccines, which were vital during the COVID-19 pandemic. 

BioPIPS consortium includes GSK, Sanofi, Nanyang Technological University, Singapore (NTU), NTUitive, National University of Singapore (NUS), and Singapore Institute of Technology (SIT).

Consortium members inked a Memorandum of Understanding (MoU) in 2022, which enabled discussions on manufacturing challenges for potential research projects.

 

Follow the link for more news on

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!